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Abstract 
TNF-α is involved in the mechanisms that initiate inflammatory bowel diseases (IBDs). Anti-TNF-
α drugs, such as infliximab (IFX), cause non-responsiveness and side effects, indicating the need to 
investigate alternative therapies for these diseases. The anti-inflammatory protein, annexin A1 
(AnxA1), has been associated with the protection of the gastrointestinal mucosa. To further address 
the role of endogenous AnxA1 on the TNF-α blockade efficacy in a murine model, we assessed 
colitis induced by dextran sulphate sodium (DSS) in wild-type (WT) and AnxA1-/- Balb/c mice 
treated with IFX. We consistently observed endogenous AnxA1 prevented clinical and 
physiological manifestations of experimental colitis treated with IFX, additionally the manifestation 
of the disease was observed earlier in AnxA1-/- mice. Rectal bleeding, diarrhea, histological score, 
epithelial damages and collagen degradation caused by DSS were prevented following IFX 
treatment only in WT mice. IL-6 increased during colitis in WT and AnxA1-/- mice, decreasing 
under IFX treatment in WT. The influx of neutrophils and TNF-α secretion were largely elevated in 
AnxA1-/- mice when compared to WT mice. In the group WT/DSS+IFX, phagocytes were more 
susceptible to apoptosis following treatment with IFX. Endogenous expression of AnxA1 increased 
after DSS and decreased with IFX treatment, demonstrating an attenuated inflammatory response. 
The data indicate that AnxA1 contributes to the establishment of intestinal homeostasis after 
blocking of TNF-α was used as a treatment of IBD, constituting a key molecule in the mechanism 
of action and a potential biomarker of therapeutic efficacy. 
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1. Introduction 
Inflammatory bowel diseases (IBDs)  (e.g. ulcerative colitis (UC) and Crohn's disease (CD)) 
are conditions characterized by inflammation of the lamina propria, which cause abdominal pain, 
diarrhea and rectal bleeding [1]. The pathogenicity of IBDs include genetic predisposition, aberrant 
immunological responses, epithelial dysfunction and altered microbial-host relationship [2]. 
Infiltrating inflammatory cells produce and are activated by a range of pro-inflammatory cytokines 
in the affected mucosa [3,4]. This cascade is followed by a loss of epithelial integrity, increased 
intestinal permeability and altered resident microbiota that propagates the inflammatory process 
and attenuates the tissue regeneration [5].  
In the acute stage of mucosa inflammation, tumor necrosis factor alpha (TNF-α) is a key 
cytokine. TNF-α is predominantly produced by macrophages in response to bacterial infections. 
Among others, TNF-α induces intestinal epithelial damage, increased adhesion molecule 
expression and enhanced vascular permeability, allowing the extravasation of cells and fluids [2,6]. 
This mechanism proposes TNF-α involvement in the development of inflammatory responses that 
activates IBDs. Since the secretion of TNF-α compromises the gastrointestinal physiology [7], 
TNF-α neutralizing therapy has been successfully utilized [8]. 
The efficacy of anti-TNF-α antibody, Infliximab (IFX), was demonstrated by inducing 
remission of the disease in patients with UC [9]. IFX is an IgG monoclonal antibody, that has 
constant regions that are from human and variable regions that are originally from mouse 
immunoglobulin [10]. This antibody strongly binds to the soluble and transmembrane forms of 
TNF-α, inhibiting this cytokine from exerting its inflammatory properties [10]. The inhibition of 
TNF-α signaling subsequently activates several anti-inflammatory effects, including mucosal 
healing, decreased pro-inflammatory cytokine release and T cells apoptosis [11]. However, some 
patients are tolerant to this therapy or still present with side effects, mainly related to opportunistic 
diseases, autoimmunity and hypersensibility [12]. The non-responsiveness to IFX treatment 
  
highlights the need to investigate alternative mediators related to the therapeutic efficacy following 
the TNF-α blockade. 
In this context, our group has recently demonstrated that treatment with IFX could induce the 
transcription, and subsequent expression, of the anti-inflammatory protein annexin A1 (AnxA1) 
[13]. This study reported that CD patients lose the ability to express systemic and mucosal AnxA1, 
which is recovered following IFX treatment. The systemic up-regulation of transcriptional 
expression and release of plasma AnxA1 was correlated with improved quality of life in these 
patients [13]. Further data demonstrated that biopsies from healthy volunteers and patients 
undergoing anti-TNF-α therapy with remittent UC, presented with higher AnxA1 expression than 
those with the active disease [14]. Together, our results demonstrate that AnxA1 is a potential key 
protein in anti-TNF-α therapy.  
AnxA1 is a glucocorticoid induced protein [15,16], whose N-terminal domain exerts anti-
inflammatory roles [17]. In the gastrointestinal tract, AnxA1 mediates the expression of cytokines 
such as, TNF-α, IL-6 and IL-10 [18]. Additionally, AnxA1 has been shown to mediate stomach 
wound healing after indomethacin treatment [19] and tissue damage recovery during IBDs [20]. 
Although the AnxA1 anti-inflammatory roles are well established, the function of this protein on 
IBDs and its interactions with TNF-α are not well understood. 
We hypothesize that endogenous AnxA1 is involved in the mechanism of action of TNF-α 
neutralization. Herein, wild-type and AnxA1 deficient mice strains are used to investigate the 
relevance of this protein on the clinical and immunomorphological effects of IFX in a murine model 
of DSS induced colitis.   
 
2. Materials and Methods 
2.1. Ethics statement and animals 
Female wild-type (WT) and AnxA1 null (AnxA1-/-) Balb/c mice aged 8- to 10-wks-old or 
20-25g were obtained from the Animal House at the School of Pharmaceutical Sciences, University 
  
of São Paulo (Brazil). The animals were housed with a 12 h light–dark cycle and allowed food and 
water ad libitum. The experiments were performed in strict accordance with the Brazilian laws of 
protection and this study was approved by the Committee on the Ethics of Animal Experiments of 
the São Paulo Federal University (UNIFESP), São Paulo, Brazil (Permit Number: 6850200715) and 
University of São Paulo (Permit number: 01200.003570/1998-08). 
 
2.2. Colitis induction and clinical analysis 
Colitis was induced by Dextran Sulphate Sodium (DSS, MW 40,000, Dextran Products 
Limited, Canada), at a concentration of 5% in sterilized drinking water [14]. Fresh DSS solution 
was replenished every two days (days 0, 2 and 4). Over seven days, development of induced colitis 
was assessed by analysis of the following parameters: percentage of body weight loss, diarrhea and 
rectal bleeding (Hemoccult Sensa). The Disease Activity Index (DAI) was calculated with 
consideration of the sum of the diary values of each score above. On day 6, mice were euthanized 
using nasal anesthesia (Isoflurane: 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane). The large 
intestine was removed and fragmented for cytokine (proximal colon), colorimetric (middle colon) 
and histopathological and immunohistochemical (distal colon) analysis.  
 
2.3. Experimental design and anti-TNF-α treatment 
WT and AnxA1-/- mice were randomly divided into the following groups (n=6 animals/group): 
oral DSS administration and intraperitoneal (i.p.) sterilized saline (group DSS); DSS administration 
and i.p. anti-TNF-α (Infliximab - IFX: REMICADE® Janssen-Cilag Pharmaceutics Ltda, 
Argentina) at 1 mg/kg (group DSS+IFX). Mice from control groups received sterilized water only 
and were injected i.p. with either saline (Sham) or IFX, to allow a comparison between sick and 
healthy conditions. The i.p. injections were performed on day 1. 
 
2.4. Myeloperoxidase measurement 
  
Neutrophil infiltration was indirectly assessed by myeloperoxidase (MPO) measurement as 
previously described [14]. Briefly, fragments of the middle colon were weighted to a correct 
calculation for the concentration. These samples were homogenized in a 5% EDTA/NaCl buffer 
(pH 4.7) and centrifuged at 10000 rpm, 4 ºC for 15 min. The pellet was resuspended in a 0.2% 
NaCl, 1.6% NaCl-5% glucose and 0.5% hexadecyl trimethyl ammonium bromide (pH 5.4) solution. 
The samples were frozen in liquid nitrogen and thawed at 37 ºC, three times. Finally, the 
supernatant was collected and 50 µL was used for the colorimetric assay. The enzymatic reaction 
was performed in a 96 well plate, and MPO was detected using tetramethylbenzidine (TMB, 
Millipore, USA). The absorbance was measured using a spectrophotometer at 450 nm and the 
concentration of MPO in ng/ml was calculated in comparison to a standard curve generated from a 
solution of horseradish peroxidase (HRP, BD Biosciences, California, USA) diluted in NaPO4. 
Results were expressed as the mean ± S.E.M. of the concentration (ng/mL/mg). 
 
2.5. Histological analyses  
Samples of the distal portion of the colon were fixed in 4% buffered formalin for 24 hours, 
dehydrated in graded ethanol and embedded in paraffin for immunohistochemical and 
histopathological analysis. 
Histopathological analysis and histological score: 2 µm sections were stained with hematoxylin & 
eosin and analyzed using a high-power objective (40X) on an Axioskop 2-Mot Plus Zeiss 
microscope (Carl Zeiss, Jena, Germany). To quantify the morphological aspects following DSS and 
IFX, a scoring system was employed. Values of 0, 1, 2 and 3 correlated to normal, mild 
abnormality, moderate damage and severe injury, respectively. The following parameters were 
considered: crypts and histoarchitecture changes, edema, ulcers and inflammatory cells located at 
the epithelium, lamina propria and submucosa [21]. Results were expressed as the mean ± S.E.M. 
Quantification of collagen: The submucosal collagen was detected by the picrosirius-hematoxylin 
staining under polarized light. Five randomized fields per animal were photographed (40x). 
  
Subsequently, 1 mm2 grid squares was designed for each field. The points were quantified that 
coincide either with intact collagen fibers or with the spots of conjunctive tissue in which these 
fibers were degraded. The proportion of intact collagen fibers/total fibers was calculated in each 
field and then to each animal. Results were expressed as the mean ± S.E.M. of the intact collagen 
fibers proportion.   
 
2.6. Immunohistochemical detection of Annexin A1 and Caspase-3 
Sections of the colon (2 µm) were incubated with sodium citrate buffer at 96 ºC for 30 min. 
The endogenous peroxide activity was blocked with 3% hydrogen peroxide for 30 min, followed by 
incubation with either polyclonal rabbit anti-AnxA1 (Zymed Laboratories, Cód. 713400, 
Cambridge, UK) at 1:500 or polyclonal rabbit anti-caspase-3 (Abcam, Cód. 552293, Cambridge, 
UK) at 1:50, in 10% TBS-BSA (Sigma-Aldrich, San Luis, USA). The slides were incubated 
overnight at 4 °C. Additionally, negative control sections were incubated with 10% TBS-BSA 
instead of the primary antibody. Following the wash step, sections were incubated with a secondary 
Ab conjugated with HRP (Abcam, Cambridge, U.K.). Positive staining was detected using 3,3'-
diaminobenzidine (DAB substrate; Invitrogen, USA). Finally, sections were counterstained with 
hematoxylin (Inlab Confiança, São Paulo, Brazil) and mounted. Analysis was conducted on 
Axioskop 2-Mot Plus Microscope (Carl Zeiss, Jena, GR), using AxioVision software for 
densitometric and quantitative analysis. Densitometric analysis was used to determine AnxA1 
intensity in colonic epithelial and immune cells (40x) on an arbitrary scale from 0 to 255, and the 
data were expressed as the mean ± S.E.M. Caspase-3 marked phagocytes (e.g. neutrophils, 
monocytes and macrophages) were quantified and the number of immunoreactive cells was divided 
by the total number of phagocytes counted in the same slides (objective 63x). Results were 
expressed as the mean ± S.E.M. of the percentage of apoptotic phagocytes in mm2. 
 
2.7. Explant culture and cytokine levels measurement in colonic tissue 
  
Colonic medial fragments were weighted and washed in sterile PBS and incubated with 
Dulbecco's Modified Eagle Medium (DMEM, Cultilab, Campinas, São Paulo, Brasil) for 24 
h, supplemented with 10 % fetal bovine serum (FBS, Cultilab) and antibiotics (Cultilab), one punch 
biopsy per 1 mL medium. The supernatants were collected and used for the assessment of IL-6 and 
TNF-α secreted levels by ELISA (BD Biosciences, California, USA), according to manufacturers 
instructions.  The data were expressed as the mean ± S.E.M. of the concentration (ng/mL/mg). 
 
2.8. Statistical analysis 
The statistics were performed using GraphPad software version 6.00. First, we performed the 
normality test Kolmogorov-Smirnov to determine if the data distribution was either parametric or 
non-parametric. Then, differences between groups were evaluated by either one-way ANOVA 
(clinical analysis) or two-way ANOVA (other analysis), followed by either Bonferroni (parametric) 
or Dunn's test (non-parametric). A probability value less than 0.05 was considered to be significant. 
 
3. Results 
3.1. IFX prevents clinical manifestations of DSS induced colitis in WT, but not in AnxA1-/- 
mice 
Initially, we assessed the clinical alterations resulting from DSS-induced colitis and the 
effects of treatment with IFX. The body weight loss was significant in WT/DSS and AnxA1-/-/DSS 
mice at days 5 and 6, in comparison to the respective sham groups (Fig 1A and B). The scores for 
diarrhea and rectal bleeding are shown in Figures 1C-1F and increased in both lineages over days 2-
6. The Disease Activity Index (DAI), defined as the sum of the scores above, was higher in the 
WT/DSS (days 2-6) and AnxA1-/-/DSS (days 1-6) mice when compared to the sham groups (Fig 1 G 
and H) confirming that DSS induced intense colitis in both strains. It is noteworthy to mention that 
symptoms of disease started earlier in the AnxA1-/- group than in WT mice.  
  
The administration of 1 mg/kg of IFX prevented diarrhea and blood loss, as well as reduced 
the DAI in the WT mice. Interestingly, knockout mice did not present with improvement in any 
clinical parameter following treatment with IFX, indicating that TNF-α blockade is not sufficient 
enough to attenuate the colitis symptoms in the absence of AnxA1. Taken together, the clinical data 
reports that WT and AnxA1-/- mice develop DSS-induced colitis with similar intensity, although 
earlier in AnxA1-/-. However, the anti-TNF-α treatment was efficient in preventing the disease 
manifestations, but only in the presence of AnxA1. 
 
3.2. DSS-induced colitis causes morphological alterations and collagen degradation in the 
colon 
WT and AnxA1-/- mice exposed to DSS and treated or non with IFX, presented with shortening 
in the length of the large intestine (Fig 2B and C). Only AnxA1-/-/DSS animals had decreased 
intestinal weight (Fig 2B). The anti-TNF-α treatment did not prevent these parameters in any 
studied strain (Fig 2B and C). 
After observing anatomic alterations, we questioned if this colitis model could induce 
microscopic alterations, specifically in collagen integrity. Therefore, we examined these fibers in 
the submucosal layers (Figs 2D-K). In this region, the collagen was degraded in the WT/DSS mice 
(Fig 2F) and, following IFX treatment, there was a trend indicating an increase in the integrity of 
these fibers (Fig 2G), however, it was not significant (Fig 2L). In AnxA1-/-/DSS and AnxA1-/-
/DSS+IFX, the picrosirius-hematoxylin polarization showed areas of degraded collagen, 
interspersed by areas of intact fibers (Figs 2J and K). We did not detect quantitative significant 
alterations on the collagen integrity in either group of mice (Fig 2L).  
 
3.3. Histological damage induced by DSS is restrained by IFX only in the presence of AnxA1 
Figure 3A-H illustrates histological results following seven days of DSS administration. The 
DSS produced alterations on the colonic histoarchitecture, compromising homeostasis in WT and 
  
AnxA1-/- mice. In both strains, the epithelial layer was interrupted in particular regions with 
occasional ulcerations over the distal portion of the colon. On the mucosal and submucosal layers of 
WT/DSS and AnxA1-/-/DSS mice, we observed edema and evident inflammatory infiltrate, mainly 
constituted by neutrophils and macrophages, indicating the severity of the disease. On the lamina 
propria, there were discontinuous areas presenting with either dysplastic or absent crypts and 
vacuolar hydropic degeneration. 
In WT mice, the treatment preserved the epithelial layer along the colon and decreased the 
vacuolar hydropic degeneration and the submucosal edema. Alternatively,  the AnxA1-/- animals 
were observed to have remaining glandular alterations and ulcers, indicating that the IFX 
administration was not efficient in recovering these histological damages in the absence of AnxA1. 
Furthermore, alterations caused by the IFX administration were not detected, thus, we are confident 
that the anti-TNF-α antibody is not involved in the induction of these specific tissue injuries (data 
not shown). 
To quantify the intensity of the induced colitis and the anti-TNF-α treatment efficacy, we 
scored the histological changes observed in each condition (Fig 3I) as described in M&M section. 
The sham and IFX groups presented with very low values of morphological alterations. Following 
exposure to DSS, both WT and AnxA1-/- mice presented with increased histological scores, 
compared to the sham group of mice. However, the treatment decreased this parameter in the 
WT/DSS+IFX mice, while no improvement was observed in the AnxA1-/-/DSS+IFX group. 
 
3.4. AnxA1 mediates the reduction of MPO and IL-6 secretion, and augments the proportion 
of phagocyte apoptosis following IFX treatment 
MPO activity, a marker of neutrophil recruitment and infiltration, was quantified for each 
condition (Figs 4A and B). Results showed that WT mice had increased activity of this enzyme 
after DSS in comparison to the sham group (Fig 4A).  We hypothesize this to be the reason why we 
observed an augmented amount of neutrophils on the colonic tissue. The treatment with IFX did not 
  
reduce levels of MPO in either the WT or AnxA1-/- groups. However, a 30-fold increase in MPO 
level was detected in AnxA1-/- mice in comparison to the WT group (Figs 4A and B).  
Furthermore, the concentrations of pro-inflammatory cytokines IL-6 and TNF-α were 
measured by ELISA assays (Figs 4C-F). The exposure to DSS increased IL-6 expression in WT and 
AnxA1-/- mice. Conversely, TNF-α was augmented only in the AnxA1-/-/DSS, presenting with levels 
150 times higher than the WT/DSS. The efficacy of the IFX treatment was evidenced by a reduction 
of IL-6 only in WT mice, highlighting the relevance of AnxA1 on the efficacy of anti-inflammatory 
actions of IFX treatment.  
Finally, we performed immunohistochemical analysis for caspase-3 to assess apoptosis of 
phagocytes in the colon (Figs 4G). In the WT/DSS group, the percentage of neutrophils, monocytes 
and macrophages marked with caspase-3 was not altered. Nevertheless, in the WT/DSS+IFX mice, 
increased apoptosis was observed in comparison to WT/sham and WT/DSS groups. AnxA1-/- mice 
did not present differences on the total apoptotic phagocytes/total phagocytes when compared to 
WT mice. Nevertheless, the treatment with IFX in the AnxA1-/-/DSS (AnxA1-/-/DSS+IFX group) did 
not improve the apoptosis of phagocytes. The percentage of apoptotic phagocytes was significantly 
lower in the AnxA1-/-/DSS+IFX group than that observed in the WT/DSS+IFX group (Figure 4G). 
 
3.5. Endogenous AnxA1 is modulated in the intestinal epithelial and immune cells following 
DSS administration and TNF-α blockade 
The immunoreactivity of the AnxA1 protein was evaluated on the colonic tissue in each of the 
different studied conditions (Fig 5). Sections were incubated with 10% TBS-BSA instead of the 
primary antibody to provide a negative control for the reaction (Fig 5F). 
In the colonic normal condition (sham), AnxA1 was detected in the epithelial cells, which 
compose the excretory portion of tubular glands. In the epithelium of healthy mice treated with IFX, 
the immunostaining for this protein was less observed (Figure 5B). 
  
Conversely, in the WT/DSS group, AnxA1 expression was significantly increased in the 
epithelial cells and immune cells (mainly neutrophils and macrophages) (Fig 5C). The previous 
blockade of TNF-α with IFX also promoted alterations to AnxA1 endogenous expression, showing 
lower levels in both epithelial cells and leukocytes (Fig 5D) when compared to the non-treated 
mice. The densitometry analysis confirmed the described observations, showing higher AnxA1 
expression during colitis and lower levels under IFX treatment (Fig 5E).  
 
4. Discussion 
 Current therapies used to suppress IBD activity still result in side effects and ineffectiveness, 
highlighting the need to research alternative messengers and biomarkers as potential treatment 
options  [22]. In the present study, we observed that the presence of the anti-inflammatory protein, 
AnxA1, is related to the efficiency of the IFX treatment in experimental colitis, constituting a 
potential biomarker of therapeutic efficacy. 
Several studies demonstrated that the colitis induced by DSS in the murine model mimics the 
clinical manifestations and the consequent increase of the DAI in humans [19,23,24], and it is a 
suitable model to detect the efficiency of IFX treatment [24]. Indeed, in this study, DSS induced a 
typical set of alterations that are characteristic of acute colitis, such as body weight loss, diarrhea 
and rectal bleeding, which were significantly reduced in the WT mice. Interestingly, these 
symptoms were not significantly reduced in AnxA1-/- mice treated with IFX, showing, for the first 
time, the involvement of endogenous AnxA1 in the clinical improvement following the TNF-α 
blockade in colitis. Moreover, clinical manifestation was detected earlier in AnxA1-/- mice, 
corroborating the AnxA1 endogenous mediation on colitis [19].  
Diarrhea and blood loss in colitis are associated with loss of epithelial cells, which are 
responsible for the absorption of water [25].  The impairment of the epithelial barrier during colitis 
is mediated by TNF-α, which also induces apoptosis of intestinal epithelial cells and necroptosis of 
goblet cells [2,26,27]. We investigated the interrelationships of these effects during colitis, and 
  
results showed diarrhea, blood loss and omitted areas of ulceration in the distal region in the colon 
of the WT and AnxA1-/- mice. Additionally, treatment with IFX largely prevented the loss of 
epithelial cells, ulceration and avoided rectal bleeding and diarrhea in WT mice. The absence of 
therapeutic effects of IFX in AnxA1-/- mice corroborated the key role of AnxA1 on IFX 
mechanisms. The exact mechanism of AnxA1 on IFX effects is not well understood, but a 
prominent role of AnxA1 on epithelial integrity is hypothesized, as AnxA1 promotes proliferation 
and migration of epithelial cells, playing an important role in tissue regeneration [19,20]. Moreover, 
this supports tight junction integrity, such as in the blood-brain-barrier [28–30].  Furthermore, we 
speculate that the preservation of the epithelial layer by IFX is not related to the direct blockade of 
the pro-inflammatory actions of TNF-α on the epithelial cells, but instead is indirectly linked with 
the AnxA1 action in protecting the mucosal histoarchitecture [19,20]. 
DSS administration altered a large portion of intestine, which was observed by decreased 
length in samples collected from WT and AnxA1-/- mice, and reduced weight of the intestine of the 
AnxA1-/- mice. The IFX did not prevent the decrease of intestinal weight and length in both strains.  
Additionally, histological evaluation provided evidence of degradation of the collagen fibers in the 
WT/DSS group, but not in the AnxA1-/-/DSS group. The degradation of the extracellular matrix 
components were demonstrated in intestinal explants from CD and UC patients, which presented 
augmented expression of MMPs-1, -2, -3 and -9 when compared to control patients [31], 
corroborating other in vivo studies [32,33]. The protein AnxA1 is also related to the upregulation of 
MMP-9 in breast cancer [34] and mediates the production of MMP-1 by TNF-α in rheumatoid 
arthritis [35]. In our study, the submucosal collagen was not damaged in the WT/DSS+IFX group 
when compared to the WT/DSS group. However, AnxA1 and IFX appear to influence tissue 
remodeling in inflammatory conditions [35,36] and in the culture of intestinal explants from 
patients with IBDs [31], further studies are needed to investigate this question. 
 The damage of the epithelial barrier in colitis allows the entrance of microbiota into the 
subjacent tissue, and the immune response occurs to control the action of potential pathogens [37]. 
  
Neutrophils and monocytes/macrophages are essential cells that support this process [38,39] by  
phagocyting the pathogens, secreting pro-inflammatory cytokines, such as IL-6 and TNF-α, 
expressing metalloproteases and generating reactive oxygen species, which contributes to 
elimination of microorganisms in the tissue [26]. Therefore, phagocytes are also intrinsically related 
to the pathogenesis of IBDs, and recent data have shown that an influx and actions of neutrophils 
and macrophages in the inflamed gut mucosal is required to provide an effecient host defense 
during colitis, nevertheless it may not be exacerbated [26,40–44]. Our data demonstrated enhanced 
neutrophil influx in DSS, corroborating previous data [45,46], and that it was approximately 30 
times higher in the AnxA1-/- mice than in WT mice. The higher neutrophil influx in AnxA1-/- mice 
was expected, as AnxA1 is a potent inhibitor of neutrophil migration from blood into tissues during 
acute inflammation [47]. Based on recent data, showing that adequate neutrophil migration in colitis 
is required for the development and resolution of inflammation, we infer that AnxA1 also controls 
colitis by avoiding an exacerbated neutrophil accumulation in the gut mucosa. Moreover, the 
relevance of neutrophils in colitis is reinforced by the fact that IFX treatment reduced DSS effects 
in WT mice, but did not reduce neutrophil influx.  This observation corroborates similar neutrophil 
influx in WT and tumor necrosis factor receptor 1 knockout mice (TNFR1-/-) in DSS induced colitis 
[14]. 
Monocytes, neutrophils and macrophages secrete high amounts of IL-6 and TNF-α during 
inflammation [26,48]. Based on our data, the expected elevated levels of these cytokines in the 
explants of inflamed DSS-induced colitis samples was observed and comparable to those found in 
the literature [45,46,48–50]. Nevertheless, the amount of cytokines, specifically TNF-α, was highly 
secreted by explants collected from AnxA1-/- mice (approximately 150-fold), which may indicate the  
higher amounts of infiltrating neutrophils and enhanced ability of both neutrophils and macrophages 
from AnxA1-/- to secrete the cytokines [41]. TNF-α is related to the more accentuated occurrence of 
ulcers, expression of adhesion molecules and vascular permeability, leading to increased blood loss 
and leukocyte transmigration. Certainly, this set of alterations confirm the results obtained from 
  
AnxA1-/- mice, in which the elevated secretion of TNF-α correlates with more extensive ulcers and 
significantly higher levels of MPO in comparison to WT mice.   
 The relevance of IL-6 in the activation of IBDs was previously described [51,52]. This 
cytokine is involved in protecting the host against microorganisms, by activating antigen presenting 
cells and T-cells and stimulating the production of other pro-inflammatory cytokines [26]. Furhter, 
we observed that the expression of IL-6 increased following DSS administration in WT and AnxA1-
/- 
mice. Additionally, the IL-6 levels were reduced following the TNF-α blockade in the WT mice, 
but not in the AnxA1-/- mice. Alternative models of inflammation have already described and report 
that IL-6 is negatively regulated by the AnxA1 protein [53,54]. Moreover, this cytokine was 
reduced in patients with rheumatoid arthritis treated with inhibitors of TNF-α [55]. These 
arguments show that IL-6 is directly influenced by the blockade of TNF-α and modulated by the 
AnxA1 protein. 
The healing of injured tissue is a complex process, and apoptosis of inflammatory cells is one 
pivotal mechanism to return the tissue integrity [56]. Our data show that inducing apoptosis of 
leukocytes is one mechanism of IFX treatment, as it markedly enhanced the percentage of caspase-3 
positive leukocytes in WT inflamed tissue, which was much higher than that observed in AnxA1-/- 
tissue. Indeed, the role of AnxA1 as a inducer of monocyte and neutrophil apoptosis, has been fully 
shown in vitro and in vivo as a mechanim of resolution of inflammation [57–59]. Therefore, 
endogenous AnxA1 mediates IFX induced apoptosis of inflammatory cells in DSS induced colitis.   
Although the possible participation of AnxA1 on the protection of the intestinal mucosa in 
models of IBDs has been increasingly described [13,20,50], the modulation of this anti-
inflammatory protein after pharmacological strategies, such as the IFX, remain unclear. Concerning 
the importance of understanding how the endogenous AnxA1 expression and roles are modulated 
by the intestinal inflammation and the anti-TNF-α intervention, we evaluated the expression of this 
protein on the colonic tissue. 
  
Previous reports have shown that the levels of endogenous AnxA1 were significantly 
increased in the epithelial and glandular cells, as well as in immune cells transmigrated to the tissue, 
as showed in other inflammatory conditions [19,60]. Additionally, we observed that IFX reduced 
AnxA1 expression in animals exposed to DSS. These data support that the blockade of TNF-α was 
sufficient to control mucosal inflammation, indicated by the reduced expression of endogenous 
AnxA1 following anti-inflammatory intervention, and the association with the resolution in several 
models of inflammation [47,61].  
In conclusion, the results indicate that the endogenous AnxA1 protein is involved in 
promoting morphological and physiological preservation on the colon during inflammatory 
conditions treated by anti-TNF-α biological therapy, constituting an important anti-inflammatory 
mediator, as well as a potential biomarker of therapeutic efficacy.  
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7. Figure legends 
Figure 1. Clinical parameters during experimental colitis and following anti-TNF-α 
treatment.  
(A and B) Loss of body weight. (C and D) Diarrhea score. (E and F) Rectal bleeding score. (G and 
H) Disease activity index (DAI). n=6 animals/group * p < 0.05; ** p < 0.01, *** p < 0.001 vs 
Sham; ## p < 0.01, ### p < 0.001 vs IFX; §§ p < 0.01, §§§ p < 0.001 vs DSS. 
 
Figure 2. Morphological analysis of the large intestine and submucosal collagen after colitis 
and anti-TNF-α treatment.  
 (A) Anatomic evaluation of the large intestine, (B and C) Intestinal weight and length. (D-G) 
Collagen in WT,. (H-K) Collagen in AnxA1-/-. Sections: 2 µm. Bar: 20 µm. Staining: Picrosirius-
Hematoxylin. (L) Collagen quantification. n=6 animals/group. * p < 0.05, ** p < 0.01, *** p < 
0.001 vs Sham; ## p < 0.01 vs IFX. Asterisk indicates degraded collagen fibers after DSS in WT  
(F)  and in AnxA1-/-/DSS and AnxA1-/-/DSS+IFX (J and K). 
 
Figure 3. Histopathological analysis of the distal colon after colitis and effects of the treatment 
with anti-TNF-α.  
 (A and E) Normal intestinal morphology, (B and F) Preserved structure after IFX, (C and G) 
Altered histoarchitecture of the colon, (D and H) Tissue injuries attenuated by IFX in WT, but not 
  
in AnxA1-/- mice. Ulcer (black arrows). Dysplasic crypts (white arrows). Vacuolar hydropic 
degeneration (asterisks). Mucosal inflammatory infiltrate (details: C, G and H). Inclusion: paraffin. 
Staining: Hematoxylin-Eosin. Sections: 2 µm. Bar: 20 µm. (I) Histological score. n = 6 
animals/group. *** p < 0.001 vs Sham; ## p < 0.01, ### p < 0.001 vs IFX; §§ p < 0.01 vs DSS.  
 
Figure 4. Expression of MPO, IL-6, TNF-α and apoptosis of phagocytes on colonic tissue and 
effects of treatment with anti-TNF-α.  
(A and B) MPO activity, (C-F) IL-6 and TNF-α secretions, (G) Proportion of apoptotic phagocytes. 
n=6 animals/group. Mean ± S.E.M. * p < 0.05, ** p < 0.01, *** p < 0.001 vs Sham; # p < 0.05, ## p 
< 0.01 vs IFX; && p < 0.01, &&& p < 0.001 vs respective WT. 
 
Figure 5. Influence of colitis and IFX treatment on AnxA1 colonic expression  
(A and B) AnxA1 expression on the secretory portion of mucosal glands (asterisks), (C) AnxA1 in 
the epithelial (black arrowheads) and inflammatory cells (black arrows) during colitis, (D) AnxA1 
in the epithelial (white arrowheads) and inflammatory cells (white arrows) after colitis treatment, 
(E) AnxA1 immunoreactivity in neutrophil, (F) Macrophage positive to AnxA1, (G) Negative 
control, (H) Densitometry: AnxA1 after DSS and IFX treatment. Sections: 2 µm. Bar: 20 µm. 
Counterstain: Hematoxylin. n=6 animals/group. * p < 0.05 vs Sham; # p < 0.05 vs IFX; § p < 0.05 
vs DSS. 
 
 
 
 
 
 
 
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
